Lebwohl M - Search Results

1

Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects.

Otley CC, Stasko T, Tope WD, Lebwohl M. Otley CC, et al. Among authors: lebwohl m. Dermatol Surg. 2006 Apr;32(4):562-8. doi: 10.1111/j.1524-4725.2006.32115.x. Dermatol Surg. 2006. PMID: 16681667

2

New roles for systemic retinoids.

Lebwohl M, Kathryn M. Lebwohl M, et al. J Drugs Dermatol. 2006 May;5(5):406-9. J Drugs Dermatol. 2006. PMID: 16703775 Review.

3

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.

Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. Menter A, et al. Among authors: lebwohl m. J Am Acad Dermatol. 2020 Jun;82(6):1445-1486. doi: 10.1016/j.jaad.2020.02.044. Epub 2020 Feb 28. J Am Acad Dermatol. 2020. PMID: 32119894

4

Combining systemic retinoids with biologic agents for moderate to severe psoriasis.

Smith EC, Riddle C, Menter MA, Lebwohl M. Smith EC, et al. Among authors: lebwohl m. Int J Dermatol. 2008 May;47(5):514-8. doi: 10.1111/j.1365-4632.2008.03470.x. Int J Dermatol. 2008. PMID: 18412874

5

The use of systemic immune moderators in dermatology: an update.

Kazlow Stern D, Tripp JM, Ho VC, Lebwohl M. Kazlow Stern D, et al. Among authors: lebwohl m. Dermatol Clin. 2005 Apr;23(2):259-300. doi: 10.1016/j.det.2004.09.006. Dermatol Clin. 2005. PMID: 15837155 Review.

6

Transition from methotrexate and cyclosporine to other therapies including retinoids, ultraviolet light and biologic agents in the management of patients with psoriasis.

Maryles S, Rozenblit M, Lebwohl M. Maryles S, et al. Among authors: lebwohl m. J Dermatolog Treat. 2003;14 Suppl 2:7-16. J Dermatolog Treat. 2003. PMID: 14578093 Review.

7

Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature.

Halverstam CP, Zeichner J, Lebwohl M. Halverstam CP, et al. Among authors: lebwohl m. J Cutan Med Surg. 2006 Nov-Dec;10(6):291-9. doi: 10.2310/7750.2006.00065. J Cutan Med Surg. 2006. PMID: 17241599 Review.

8

Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies.

Lebwohl M, Menter A, Weiss J, Clark SD, Flores J, Powers J, Balin AK, Kempers S, Glinert RJ, Fleming T, Liu Y, Graeber M, Pariser DM. Lebwohl M, et al. J Drugs Dermatol. 2007 Apr;6(4):428-35. J Drugs Dermatol. 2007. PMID: 17668541 Clinical Trial.

9

Treatment of mycosis fungoides with oral bexarotene combined with PUVA.

Stern DK, Lebwohl M. Stern DK, et al. Among authors: lebwohl m. J Drugs Dermatol. 2002 Sep;1(2):134-6. J Drugs Dermatol. 2002. PMID: 12847736

10

Overview on desonide 0.05%: a clinical safety profile.

Wong VK, Fuchs B, Lebwohl M. Wong VK, et al. Among authors: lebwohl m. J Drugs Dermatol. 2004 Jul-Aug;3(4):393-7. J Drugs Dermatol. 2004. PMID: 15303783 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

716 results

Search Page